157 related articles for article (PubMed ID: 22971215)
1. Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.
Abouyahya I; Alhan C; Westers TM; te Boekhorst PA; Kappers-Klunne MC; Coenen JL; Heyning FH; Huls GA; de Wolf JT; Imholz AL; Koene HR; Veth G; de Kruijf EJ; Muus P; Planken EV; Segeren CM; Vasmel WL; van der Velden AM; Velders GA; Koedam J; Ossenkoppele GJ; van de Loosdrecht AA
Leuk Lymphoma; 2013 Apr; 54(4):874-7. PubMed ID: 22971215
[No Abstract] [Full Text] [Related]
2. Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.
Jädersten M; Karsan A
Haematologica; 2011 Feb; 96(2):177-80. PubMed ID: 21282717
[No Abstract] [Full Text] [Related]
3. Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
Azaceta G; Calasanz MJ; Dourdil V; Bonafonte E; Izquierdo I; Palomera L
Leuk Lymphoma; 2010 Oct; 51(10):1941-3. PubMed ID: 20846100
[No Abstract] [Full Text] [Related]
4. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
[No Abstract] [Full Text] [Related]
5. Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
Göhring G; Lange K; Hofmann W; Nielsen KV; Hellström-Lindberg E; Roy L; Morgan M; Kreipe H; Büsche G; Giagounidis A; Schlegelberger B
Leukemia; 2012 Feb; 26(2):356-8. PubMed ID: 21799512
[No Abstract] [Full Text] [Related]
6. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
[No Abstract] [Full Text] [Related]
7. Lenalidomide in del 5q MDS: responses and side effects revisited.
Tiu RV; Sekeres MA
Leuk Res; 2011 Nov; 35(11):1440-1. PubMed ID: 21764127
[No Abstract] [Full Text] [Related]
8. The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed.
Kuendgen A
Leuk Res; 2014 Mar; 38(3):287-8. PubMed ID: 24433864
[No Abstract] [Full Text] [Related]
9. A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.
Voutsadakis IA; Cairoli A
Leuk Lymphoma; 2012 May; 53(5):779-88. PubMed ID: 21955212
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
11. The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells.
Mohr B; Oelschlaegel U; Thiede C; Stewart MM; Ehninger G; Platzbecker U
Haematologica; 2009 Mar; 94(3):430-1. PubMed ID: 19181778
[No Abstract] [Full Text] [Related]
12. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
13. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.
Giagounidis AA; Kulasekararaj A; Germing U; Radkowski R; Haase S; Petersen P; Göhring G; Büsche G; Aul C; Mufti GJ; Platzbecker U
Leukemia; 2012 Apr; 26(4):855-8. PubMed ID: 21960245
[No Abstract] [Full Text] [Related]
14. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
Nomdedeu M; Maffioli M; Calvo X; Martínez-Trillos A; Baumann T; Díaz-Beyá M; Aguilar JL; Rozman M; Costa D; Esteve J; Cervantes F; Colomer D; Nomdedeu B
Leuk Res; 2011 Sep; 35(9):1276-8. PubMed ID: 21764129
[No Abstract] [Full Text] [Related]
15. Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment.
Knop S; Einsele H; Bargou R; Cosgrove D; List A
Leuk Lymphoma; 2008 Feb; 49(2):346-9. PubMed ID: 18231924
[No Abstract] [Full Text] [Related]
16. Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
Cannella L; Latagliata R; Breccia M; Carmosino I; Loglisci G; Volpicelli P; Ferretti A; Santopietro M; Vozella F; Girmenia C; Cuzzola M; Oliva EN; Alimena G
Ann Hematol; 2012 Feb; 91(2):309-10. PubMed ID: 21625998
[No Abstract] [Full Text] [Related]
17. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
Platzbecker U; Braulke F; Kündgen A; Götze K; Bug G; Schönefeldt C; Shirneshan K; Röllig C; Bornhäuser M; Naumann R; Neesen J; Giagounidis A; Hofmann WK; Ehninger G; Germing U; Haase D; Wermke M
Leukemia; 2013 Jun; 27(6):1403-7. PubMed ID: 23354011
[No Abstract] [Full Text] [Related]
18. The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).
Sekeres MA; Swern AS; Giagounidis A; List AF; Selleslag D; Mittelman M; Schlegelberger B; Göhring G; Li JS; Sugrue MM; Fenaux P
Blood Cancer J; 2018 Sep; 8(10):90. PubMed ID: 30291223
[No Abstract] [Full Text] [Related]
19. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
[TBL] [Abstract][Full Text] [Related]
20. Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
Breccia M; Cannella L; Latagliata R; Nanni M; Santopietro M; Loglisci G; Ferretti A; Barzotti R; Oliva EN; Alimena G
Leuk Res; 2011 Jun; 35(6):e69-70. PubMed ID: 21232796
[No Abstract] [Full Text] [Related]
[Next] [New Search]